Safety and Efficacy Study of Depelestat in Acute Respiratory Distress Syndrome (ARDS) Patients

Phase 2

Completed

• Conditions: Fibrosis; Lung Disease; Respiratory Disorders; Respiratory Distress Syndrome, Adult; Acute Respiratory Distress Syndrome; Pulmonary Fibrosis; Inflammation
• Interventions: Drug: Placebo; Drug: EPI-hNE4

• Registration Number: NCT00455767
• Lead Sponsor: Debiopharm International SA

Brief Summary

The study is aimed to assess safety of Depelestat treatment, as well as efficacy on prevention and treatment of alveolar inflammation in early pulmonary fibrosis in patients suffering from persistent Acute Respiratory Distress Syndrome.

Detailed Description

This is a multicenter, randomised, double-blind, parallel groups, placebo-controlled, 1 week treatment of Depelestat, in patients suffering from persistent ARDS.

Patients admitted in the intensive care unit presenting ARDS criteria persistent for 12 hours to 24 hours, will be randomly assigned to the treatment by Depelestat or placebo, after a pre-treatment period as short as possible with a maximum of 48 hours since ARDS criteria are met. During the pre-treatment period, the informed consent will be obtained from the legally authorized relative of the patient, and pre-treatment biological and functional examinations will be performed, particularly blood samples and BAL for biological parameters measurement, and ventilatory mechanics, for assessment of static compliance of the respiratory system.

After the pre-treatment period, the patient will receive treatment by Depelestat or placebo during 7 days, or until extubation of the patient if this occurs before 7 days of treatment. During this treatment period, the patient will be submitted to a daily measurement of static compliance of the respiratory system, as long as the patient adaptation to 24 hours after mechanical ventilation allows the procedure, and at 96 initiation of treatment, to a blood sampling and a bronchoalveolar lavage for several biological parameters assessment.

On the first and last day of administration, blood will be also collected for pharmacokinetic evaluation.

During the post-treatment period, the patient will be submitted, at 48 h ± 24 h after the end of treatment, to a blood sampling and a BAL (this BAL is not performed when contraindication criteria are present, if the patient is already extubated, and in case of planed extubation during the subsequent 24 hours) for several biological parameters assessment, and a daily measurement of static compliance as long as the patient adaptation to mechanical ventilation allows the procedure. Patients already extubated will not be submitted to BAL nor to static compliance measurements.

After the end of the treatment, patients will be followed daily for 28 days after the diagnostic of ARDS, or until death whichever occurred first.

The duration of the study for each survivor patient will be 28 days. Survivors to day 28 will be contacted monthly to assess survival and fill in a QOL questionnaire on days 60 and 90.

Study Timeline

• Study Start: 2006-07
• Study First Submitted: 2007-03-14
• Study First Submitted QC: 2007-04-03
• Study First Posted: 2007-04-04
• Primary Completion: 2007-09
• Study Completion: 2007-09
• Status Verified: 2008-06
• Last Update Submitted: 2008-06-23
• Last Update Posted: 2008-06-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 84

Inclusion Criteria

• Patients suffering from persistent ARDS as defined by the American and European Consensus Conference on ARDS, 1994

Exclusion Criteria

• ARDS secondary to traumatism
• Pulmonary emphysema on pulmonary fibrosis
• Lung pneumocystosis
• Bronchopleural fistula
• Systemic corticosteroid treatment for more than 2 weeks before inclusion
• Severe organ disease excepted renal

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
2	Placebo	Placebo
1	EPI-hNE4	Depelestat

Primary Outcome Measures

Name	Time	Method
Static compliance relative change from pre-treatment to last on treatment

Secondary Outcome Measures

Name	Time	Method
PCPIII and cytokines concentration, as well as neutrophil influx relative change in BAL fluid from pre-treatment to post-treatment

Trial Locations

Locations (14)

Claude Guerin; 🇫🇷 Lyon, France

Laurent Brochard; 🇫🇷 Créteil Cedex, France

Jean-François Timsit; 🇫🇷 Grenoble Cedex 09, France

Samir Jaber; 🇫🇷 Montpellier Cedex 05, France

Alain Mercat; 🇫🇷 Angers, France

Yves Castaing; 🇫🇷 Bordeaux, France

Jean-Yves Fagon; 🇫🇷 Paris Cedex 15, France

Jean-Daniel Chiche; 🇫🇷 Paris Cedex, France

Jean-Jacques Rouby; 🇫🇷 Paris, France

Massimo Antonelli; 🇮🇹 Roma, Italy

Jean-Christophe Richard; 🇫🇷 Rouen Cedex, France

Jean-Michel Arnal; 🇫🇷 Toulon, France

Fekri Abroug; 🇹🇳 Monastir, Tunisia

Jordi Mancebo D.; 🇪🇸 Barcelona, Spain